Physician profile
Keith Cooper
NPI 1295732816
$2,369.87
in general payments reported to CMS, 2019-2025
27 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $200 · 2021: $595 · 2022: $536 · 2023: $214 · 2024: $166 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $331.31 | 2021-2025 | Qulipta |
| Abbott Laboratories | $325.97 | 2021-2023 | Freestyle Libre 3, Freestyle Libre |
| Novo Nordisk INC | $281.48 | 2019-2024 | |
| Pfizer INC. | $197.90 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $160.03 | 2019-2021 | |
| Lilly USA, LLC | $144.25 | 2019-2024 | Jardiance, Mounjaro |
| Novartis Pharmaceuticals Corporation | $135.43 | 2019-2022 | |
| Amgen INC. | $124.64 | 2019-2022 | |
| Amarin Pharma, INC. | $117.73 | 2019-2022 | |
| Medline Industries LP | $98.59 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $79.25 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $63.09 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.73 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.68 | 2021-2023 | Xifaxan, Trulance |
| Vanda Pharmaceuticals INC. | $37.96 | 2019-2025 | Fanapt |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $28.92 | 2021-2022 | |
| Antares Pharma, INC. | $19.87 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.93 | 2019 | |
| Genentech USA, INC. | $16.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2020 | |
| Dexcom, INC. | $13.83 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $13.10 | 2024 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $13.08 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.21 | 2019 | |
| Phathom Pharmaceuticals, INC. | $12.14 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $11.67 | 2021 | |
| Sumitomo Pharma America, INC. | $9.81 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.